Unknown PHASE2/PHASE3 INTERVENTIONAL 2-arm NCT03373708

Risk and Clinical Benefit of Chemotherapy and Intensive Endocrine Therapy for Luminal B1 Early-stage Breast Cancer

Prospective Randomized Controlled Study on the Risk and Clinical Benefit of Chemotherapy and Intensive Endocrine Therapy for Luminal B1 Early-stage Breast Cancer

Sponsor: Zhiyong Yu

Conditions Breast Cancer Chemotherapy Endocrine Breast Diseases

Interventions Cyclophosphamide Docetaxel Epirubicin Goserelin acetate Letrozole Tamoxifen

Updated 6 times since 2017 Last updated: Dec 14, 2017 Started: Dec 20, 2017 Primary completion: Dec 20, 2019 Completion: Dec 20, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2/PHASE3 clinical study on Breast Cancer and Chemotherapy, this trial is ongoing. The trial is conducted by Zhiyong Yu and has accumulated 6 data snapshots since 2017. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2/PHASE3

Status: Unknown Status → Unknown · Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2_PHASE3
Jan 2020 — Jan 2021 [monthly]

Unknown Status PHASE2_PHASE3

Status: Not Yet Recruiting → Unknown Status
Jun 2018 — Jan 2020 [monthly]

Not Yet Recruiting PHASE2_PHASE3

▶ Show 1 earlier version

Dec 2017 — Jun 2018 [monthly]

Not Yet Recruiting PHASE2_PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Zhiyong Yu

Data source: Shandong Cancer Hospital and Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.